Autumn daemons are narrower: from cyberpharmacology to clinical revelation
The old drug is new, the anti-inflammation plus the anti-fibrosis two-way, providing new ideas for a narrower heart support
The narrowness of the frame (isr) remains a challenge after coronary intervention. While traditional drug stasis inhibits smooth muscle proliferation, it has limited impact on inflammation and vascular repair. Recent studies have found that the classic anti-inflammation drug, autumn quisine, may provide an entirely new approach to isr control by simultaneously regulating the three key target points of tgf-beta1, icam1, vcam1 and limiting it from the “inflammation + fibrosis” dual path. Today we are going to read the study in depth and tell you what this means for post-scaffold patients。
Clinical background: isr - “unsatisfactory needs” after the stand
The drug stubble (ds) has significantly reduced the incidence of isrs, but between 1 and 2 per cent of patients continue to have a narrower incidence each year, accounting for about 10 per cent of all pci cases. Current mainstream dds drugs (e. G., siromos, viviolet alcohol) are mainly inhibiting cell proliferation of smooth muscles, but have limited response to inflammation and internal skin restoration and may even slow angiological healing。
Clinical pain points: the search for drugs that are both anti-inflammatory, anti-fibrotic and protective of inner skin functions is an important direction for isr control. Autumn daring is a potential candidate in this direction。
Ii. Research design: web pharmacology + double validation of animal experiments
This study uses the strategy of "web pharmacological prediction + rat carotid carving model validation" to ensure both theoretical depth and experimental support:
Core discovery: two paths regulatory mechanism for autumn quasi 1. Anti-inflammation path: inhibition of inner-white cell adhesive 2. Anti-fibrosis path: interpression of tgf-beta1 signal 3. Complementarity advantages with traditional des drugs
Traditional dds drugs (e. G. Siromos) play a major role in vsmc proliferation。
Autumn pixie base, on the other hand, compensates for the inadequacy of existing treatments in the “inflammatory driver narrower” by fighting inflammation plus fibrosis。
Iv. Clinical revelations: who could benefit from the autumn spectrum
Based on the above-mentioned mechanisms, the following three categories of patients are likely to benefit more from assistive treatment of the autumn spectrum:
Analysis of potential beneficiaries
Type of patient
Potential benefits
High inflammation
(diabetic, chronic inflammation)
More visible inhibition is more narrow
Complex pathologies
Fork, long pathologies
It may reduce the risk of re-establishment of narrower and target diseases
Des post-operative catch-up phenomenon
Bridging the limitations of a single anti-malarial drug
In addition, the study suggests that the autumn phenomenon can form a combination of dds with drugs such as siromos and achieve synergies between "anti-accumulation + anti-inflammation" that deserve further clinical exploration。
Directly available reference options: what do patients do at this stage
Although the narrowness of the autumn spectrum used in the prevention and control support frame is still at the research stage, the following proposals for action are of practical guidance to patients after the operation:
Three principles of post-operative anti-inflammation management
Control of systemic inflammation levels: strict management of chronic inflammation conditions such as diabetes, obesity and chronic dental diarrhea, are important drivers of even narrowerness。
2 regulating anti-sculpable plate + tatin treatment: the anti-inflammatory effect of hissing medicine itself is a post-operative cornerstone and cannot be suspended。
3 following the progress of clinical research: in the case of high-risk and narrower patients (diabetes mellitus, multiple pathologies, a narrower history of repeated stairwells), consultations can be conducted on the involvement of cardiologists in clinical trials related to autumn daline or in the evaluation of the application of superscripts。
️ special reminder: autumn cuisine treatment windows are narrow, with a conventional dose of 0. 5 mg between 1-2 times a day, and excessive gastrointestinal reaction or bone marrow inhibition. No “preventive stair” adaptation certificate has yet been approved, and patients must not buy it for themselves and must use it after the risk and benefit have been fully assessed by the cardiologist。
Autumn cuisine suppresses the stairwell by dichotomy between icam1/vcam1 and tgf-β1
V. Research limitations (objectively)
As a classic anti-inflammatory drug, the autumn phenomenon is moving from an “adrrhea drug” to a “cardovascular new star”. The study was validated through systematic web pharmacology and experiments, revealing its multi-targeting and two-way mechanism in isr. Autumn cuisine may be an isr treatment option for high-risk patients or provide a new combination of drug strategies for the next generation of "anti-inflammation+anti-embracing" des。
Key point
Autumn pixieline provides new multi-target intervention lines for the narrower treatment of the stairwell by regulating tgf-beta1, icam1, vcam1 and inhibiting inflammation and fibrosis。
From network pharmacology to animal experiments, the autumn phenomenon presents a unique potential for further narrowness within the anti-resort. Maintaining healthy lifestyles, controlling inflammatory conditions and regulating medications remain the most reliable strategies for patients with post-occult coronary heart disease. More high-quality clinical research in the future is expected to move this “new use of old drugs” to practical applications that will serve as a source of relief for more people at risk。
This paper, which is a front-line medical science, is based on published online pharmacology and experimental animal studies and is not a direct basis for clinical treatment. You must consult your physician for specific medications and intervention strategies。
~ original content ~ a narrow new perspective within the frame
